Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALK202 in advanced solid tumors
NCT06707610Phase 1Recruiting
- Sponsor
- Shanghai Allink Biotherapeutics Co., Ltd.
- Start
- Feb 2025
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of ALK202 in solid tumor (advanced stage), sponsored by Shanghai Allink Biotherapeutics Co., Ltd. Primary endpoints: Safety and Tolerability, Maximum Tolerated Dose and 1 more. Started Feb 2025; status: recruiting.
02
Drugs
ALK202
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06707610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06707610.